ATYR

Insider Trades

Name	Value	Action	Price	Current Price
Schimmel PaulDirector $50k100k shares BuyMay 27, 2026 $0.4963 --
Broadfoot Jill MarieChief Financial Officer $1.5k1.6k shares SellFeb 4, 2026 $0.976 --
Denyes NancyGeneral Counsel $1.1k1.1k shares SellFeb 4, 2026 $0.9761 --
Shukla SanjayDirector, Officer: President And CEO $3.7k3.7k shares SellFeb 4, 2026 $0.976 --
Schimmel PaulDirector $299k318k shares BuyOct 9, 2025 $0.9414 --
Schimmel PaulDirector $612k682k shares BuyOct 8, 2025 $0.898 --

News

globenewswire.comaTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Updateglobenewswire.comMay 15

globenewswire.comaTyr Pharma to Participate in Upcoming Investor Conferencesglobenewswire.comMay 13

seekingalpha.comaTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results Transcriptseekingalpha.comMay 12

marketbeat.comaTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trialmarketbeat.comMay 11

globenewswire.comaTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meetingglobenewswire.comMay 11

Trade ATYR

About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

CEO: Sanjay S. Shukla
IPO Date: May 7, 2015

Market Data

Open: $0.4762
High: $0.4848
Low: $0.4502
Volume: 1.3M
Avg Volume: 2.3M
52W High: $7.29
52W Low: $0.395

Valuation

Market Cap: $44M
Enterprise Value: $46M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-62M
Revenue: $190k
Net Income: $-74M
Cash: $11M
Debt: $12M

Events

EarningsAug 6

EPS est. -0.15